Evert Homan

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Thomas Helledays Stiftelse for Medicinsk Forskning, Amgen Inc., Biovitrum Ab. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Evert Homan. Retrieved from https://idiyas.com/inventor/evert-homan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 60.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 11.9

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

5 out of 10

Thomas Helledays Stiftelse for Medicinsk Forskning

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12357634 - 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy (2025-07-15),

2. 11504368 - 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy (2022-11-22),

3. 10632125 - MTH1 inhibitors for treatment of inflammatory and autoimmune conditions (2020-04-28),

4. 10179790 - MTH1 inhibitors for treatment of cancer (2019-01-15),

5. 10064869 - MTH1 inhibitors for treatment of inflammatory and autoimmune conditions (2018-09-04),

6. 9233946 - Sulfonamide compounds (2016-01-12),

7. 8686011 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2014-04-01),

8. 8541592 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (2013-09-24),

9. 7807700 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2010-10-05),

10. 7253196 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2007-08-07),

Title: Evert Homan: Innovator in Pharmaceutical Chemistry

Introduction

Evert Homan is a notable inventor based in Sollentuna, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of therapeutic compounds. With a total of 10 patents to his name, Homan's work has the potential to impact various medical treatments.

Latest Patents

Homan's latest patents include the development of 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives. These compounds are useful in therapy for the treatment of cancers, inflammation, autoimmune diseases, and graft-versus-host diseases, particularly in transplantation patients. The patents also cover pharmaceutical compositions comprising these compounds or their salts, along with methods for preparing them.

Career Highlights

Throughout his career, Evert Homan has worked with prominent companies in the pharmaceutical industry, including Amgen Inc. and Biovitrum AB. His experience in these organizations has allowed him to refine his expertise and contribute to innovative solutions in medicine.

Collaborations

Homan has collaborated with several professionals in his field, including Martin Henriksson and Martin Scobie. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.

Conclusion

Evert Homan's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to advancing medical science. His work has the potential to improve treatment options for various diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.